Indazole to 2-cyanoindole scaffold progression for mycobacterial lipoamide dehydrogenase inhibitors achieves extended target residence time and improved antibacterial activity.

Tuberculosis lipoamide dehydrogenase mycobacteria on-target residence time tight binding inhibitor

Journal

Angewandte Chemie (International ed. in English)
ISSN: 1521-3773
Titre abrégé: Angew Chem Int Ed Engl
Pays: Germany
ID NLM: 0370543

Informations de publication

Date de publication:
12 Jul 2024
Historique:
revised: 10 06 2024
received: 16 04 2024
accepted: 11 07 2024
medline: 13 7 2024
pubmed: 13 7 2024
entrez: 12 7 2024
Statut: aheadofprint

Résumé

Tuberculosis remains a leading cause of death from a single infection worldwide. Drug resistance to existing and even new antimycobacterials calls for research into novel targets and unexplored mechanisms of action. Recently we reported on the development of tight-binding inhibitors of Mycobacterium tuberculosis (Mtb) lipoamide dehydrogenase (Lpd), which selectively inhibit the bacterial but not the human enzyme based on a differential modality of inhibitor interaction with these targets. Here we report on the striking improvement in inhibitor residence time on the Mtb enzyme associated with scaffold progression from an indazole to 2-cyanoindole. Cryo-EM of Lpd with the bound 2-cyanoindole inhibitor 19 confirmed displacement of the buried water molecule deep in the binding channel with a cyano group. The ensuing hours-long  improvement in on-target residence time is associated with enhanced antibacterial activity in axenic culture and in primary mouse macrophages. Resistance to 2-cyanoindole inhibitors involves mutations within the inhibitor binding site that have little effect on inhibitor affinity but change the modality of inhibitor-target interaction, resulting in fast dissociation from Lpd. These findings underscore that on-target residence time is a major determinant of antibacterial activity and in vivo efficacy.

Identifiants

pubmed: 38997232
doi: 10.1002/anie.202407276
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202407276

Informations de copyright

© 2024 Wiley‐VCH GmbH.

Auteurs

Ruslana Bryk (R)

Weill Cornell Medicine, Microbiology and Immunology, 413 East 69 Street, BRB-11, 10065-4805, New York, UNITED STATES OF AMERICA.

Shan Sun (S)

Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

John Ginn (J)

Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

Tomasz Kochanczyk (T)

Sloan-Kettering Institute, Structural Biology, 1275 York Avenue, 10065, New York, UNITED STATES.

Nancy Arango (N)

Sloan-Kettering Institute, Structural Biology, 1275 York Avenue, 10065, New York, UNITED STATES.

Xiuju Jiang (X)

Weill Cornell Medicine, Microbiology and Immunology, 413 East 69 Street, BRB-11, 10065-4805, New York, UNITED STATES.

David J Huggins (DJ)

Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

James Bean (J)

Sloan-Kettering Institute, Immunology, 1275 York Avenue, 10065, New York, UNITED STATES.

Mayako Michino (M)

Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

Leigh Baxt (L)

Sanders Tri-Institutional Therapeutics Discovery Institute, Biology, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

Nigel Liverton (N)

Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

Peter T Meinke (PT)

Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.

Classifications MeSH